3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
59
Leukemia
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Gastrointestinal Stromal Tumors
12
Leukemia, Myeloid, Chronic-Phase
11
Neoplasms
5
Blast Crisis
4
Recurrence
3
Bronchiolitis Obliterans Syndrome
3
Synovitis, Pigmented Villonodular
2
Philadelphia Chromosome
2
Neoplasm Metastasis
2
Melanoma
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Myeloid
2
Hematologic Diseases
2
Bone Marrow Diseases
2
Sarcoma
1
Piebaldism
1
Neurofibromatoses
1
Neurofibroma, Plexiform
1
Neurofibroma
1
Neoplastic Processes
1
Myeloproliferative Disorders
1
Mucosal Lentiginous Melanoma
1
Mastocytosis, Systemic
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Hypereosinophilic Syndrome
1
Interventions
nilotinib
1
glutathione pegylated liposomal doxorubicin
1
ficlatuzumab
1
Zoledronic Acid
1
Trastuzumab
1
Radiosurgery
1
Pemetrexed
1
MRX-2843
1
Denosumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplastic Processes
×
nilotinib
×
Clear all
NCT01844765
2021-04-22
DIALOG
Novartis
Phase 2
Completed
59 enrolled
33 charts
1 FDA